Asthma treatment

21. wire (USA) – May 20, 2008 Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS, Findings of Observational Study Presented at American Thoracic Society Annual Meeting PRNewswire — Patients with asthma not adequately controlled on the inhaled corticosteroid fluticasone propionate (FP) alone experienced significant reduction in severe exacerbations when switched to the equivalent dose of FP combined with salmeterol administered as Advair Diskus(R) (fluticasone propionate and salmeterol inhalation powder) compared with patients who received a double dose of FP. The findings from an observational study were presented today at the International Conference of the …. News & Observer, The (Raleigh, NC) – February 22, 2007 Drug helps breathing A study published today could help GlaxoSmithKline expand the market for its asthma drug Advair into a growing group of patients with life-threatening lung disease. The three-year study, reported in The New England Journal of Medicine, shows that Advair reduced the frequency of flare-ups from chronic obstructive pulmonary disease, or COPD, requiring steroids, antibiotics or hospitalization by 25 percent. However, the study fell short of meeting the statistical threshold for ….. (PA) – December 12, 2008 FDA panel: Keep Advair on the market A committee of experts yesterday unanimously said Advair, GlaxoSmithKline P. L. C. ’s best-selling drug, was safe enough to remain on the market to treat asthma, but declared two other drugs too risky. The panel convened by the Food and Drug Administration also urged the agency and drug companies to study more carefully whether certain asthma drugs were safe to use in children. The panel of outside experts had been examining the safety of four asthma drugs – ….. (PA) – December 12, 2008 FDA panel: Keep Advair on the market Dec. 12–A committee of experts yesterday unanimously said Advair, GlaxoSmithKline P. L. C. ’s best-selling drug, was safe enough to remain on the market to treat asthma, but declared two other drugs too risky. The panel convened by the Food and Drug Administration also urged the agency and drug companies to study more carefully whether certain asthma drugs were safe to use in children. The panel of outside experts had been examining the safety of four asthma drugs — …. 25. McClatchy-Tribune Regional News (USA) – December 12, 2008 FDA panel: Keep Advair on the market Dec. 12 A committee of experts yesterday unanimously said Advair, GlaxoSmithKline P. L. C. ’s best-selling drug, was safe enough to remain on the market to treat asthma, but declared two other drugs too risky. The panel convened by the Food and Drug Administration also urged the agency and drug companies to study more carefully whether certain asthma drugs were safe to use in children. The panel of outside experts had been examining the safety of four asthma drugs …. 26. wire (USA) – August 8, 2007 GSK Receives Decision From FDA on Advair(R) 500/50 for COPD PRNewswire-FirstCall — GlaxoSmithKline (NYSE: GSK) announced today that the U. S. Food and Drug Administration (FDA) has issued a not approvable letter for the supplemental drug application for the 500/50 strength of Advair Diskus(R) (fluticasone propionate and salmeterol inhalation powder) in the treatment of patients with chronic obstructive pulmonary disease (COPD). The FDA questioned how Advair 500/50 compared to the currently approved 250/50 strength in order to allow for …. wire (USA) – November 12, 2008 Advair Is Positioned Ahead of Spiriva In First and Second Lines of Therapy for the Treatment of Chronic Obstructive Pulmonary Disease, Symbicort Will Be Used More Frequently in Second-Line Therapy Over the Next Two Years, According to a New Report from Decision Resources PRNewswire — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline’s Advair is positioned ahead of Boehringer Ingelheim/Pfizer’s Spiriva in first and second lines of therapy for chronic obstructive pulmonary disease (COPD). Advair captures 55. 3 percent of its total patients from first- and second-lines of therapy whereas Spiriva captures 51. 4 percent. Advair also ….. News & Observer, The (Raleigh, NC) – April 26, 2005 Racing to replace GSK drug Gilbert S. Mott Jr. and Paul J. Atkins used to work together on forerunners of GlaxoSmithKline’s Advair, a purple-and-white dispenser filled with two asthma drugs that generated about $4. 5 billion in sales last year. Now, the two former colleagues are competitors in a race to develop the next generation of asthma drug dispensers. Both lead start-ups in the Triangle: Mott is chief executive of Respirics, a Raleigh company with nine full-time employees. Atkins is …. 29. – November 21, 2005 Advair warning won’t dent sales — analyst While shares of GlaxoSmithKline slipped 5 percent in the wake of new label warnings for the British firm’s asthma drugs Advair Diskus and Serevent Diskus, an industry analyst predicted that the labeling update won’t cause much of a ripple in sales of top seller Advair over the long term. The Food and Drug Administration late last week requested that GSK and Schering -Plough add new labeling to their asthma drugs — belonging to a drug class called beta agonists — ….. CNW Group (Canada) – February 22, 2007 Results from landmark study suggest that Advair(R) provides important benefits for patients with COPD New England Journal of Medicine today publishes results of largest ever COPD study and the first to investigate the effect of treatment on the risk of death from this progressive, life-threatening lung disease TORONTO, Feb. 22 /CNW Telbec/ – An international study published in today’s New England Journal of Medicine showed that patients with Chronic Obstructive Pulmonary Disease (COPD) who took Advair(R) Diskus(R) 50/500 mcg (salmeterol and fluticasone ….